

# HUMAN PAPILLOMAVIRUS (HPV) VACCINE PROGRAMME RELAUNCH

BOARD MEETING  
Jalaa' Abdelwahab  
7-8 December 2022, Geneva, Switzerland

[gavi.org](http://gavi.org)


WE ARE VAXXED AGAINST  
CERVICAL CANCER



ARE PROTECTED AGAINST CERVICAL CANCER

# HPV vaccination – a high impact programme - has gone through several setbacks requiring a relaunch for Gavi 5.1

## Historical background



## Reach to date


- ✓ Girls reached: **9.8M**
- ✓ Introductions: **28 Routine & 9 MACs**
- ✓ Gavi 73 coverage: **11% HPV1, 9% HPV2**
  - Large countries yet to introduce
  - Mixed country-level performance

# With the proposed HPV relaunch, ≈86 million girls could be reached by 2025

## Positive enablers for rebuilding momentum

- SAGE 1-dose schedule permissive recommendation
- Increased supply (expected to triple 2022-2025)
- Acute phase of pandemic slowed

**Drivers: 1 dose adoption, catch ups for missed cohorts up to 18 years, accelerate large countries incl. MICs/India**



# The relaunch will include four key shifts estimated ≈ US\$ 167 million



## 1. Accelerate adoption of 1 dose: Vaccine US\$ 69 m, cash grants US\$ 9 m

Maintain VIG/Ops; switch grants; expand age cohort to 18 years for 'delayed' MACs; update HPV market shaping roadmap



## 3. Enhanced technical assistance: US\$ 30 m

(Global/regional/country level)

Decision-making & introductions; reinforced planning & implementation; multi-sectoral programming; advocacy & financing



## 2. HSS investments: US\$ 40 m

Cost-effective, pro-equity service delivery models; demand generation; strengthen data systems



## 4. Learning agenda: US\$ 15 m

Integration of HPV vaccine in routine delivery mechanisms & PHC; 'HPV+' cost-effective packages; impact & feasibility evaluations



# Recommendation

The Gavi Alliance Programme and Policy Committee **recommends** to the Gavi Alliance Board that it:

- a) **Approve** the four strategic shifts for the HPV programme relaunch, which are:
1. To facilitate and accelerate adoption of a permissive 1-dose schedule and support recovery of original and missed cohorts up to 18 years of age for countries with delayed multi-age cohort (MAC) vaccinations;
  2. Optimise and increase the relevant HSS investments/mechanisms that support accelerating and strengthening of the HPV programme;
  3. Enhanced technical assistance through Technical Country Assistance (TCA) and Foundational Support (FS);
  4. Learning agenda support through Strategic Focus Area (SFA) for integration of the HPV vaccination programme in routine immunisation delivery mechanisms and Primary Health Care (PHC)
- b) **Note** that the HPV vaccine has amongst the highest impact of all Gavi-supported vaccines and **request** that the Secretariat update the Programme and Policy Committee twice annually on implementation progress and return to the Board should further funding or flexibilities be needed to deliver on the ambitious relaunch agenda.

# Thank you